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Abstract: This study aimed at exploring atopic dermatitis (AD) prevalence in children and exhaustively
analyzing their comorbidity. We conducted a descriptive analysis of their socio-demographic and
comorbidity characteristics in the EpiChron Cohort (Aragón, Spain). Adjusted odds ratios (OR) were
calculated for each comorbidity using logistic regression models. In total, 33,591 children had a
diagnosis of AD, resulting in an overall prevalence of 15.5%. AD prevalence was higher in girls
compared to boys, in 3–9-year-olds compared to children of other ages, and in Spanish children
compared to those of other nationalities. Multimorbidity was present in 43% of children, with the
most frequent chronic comorbidities being asthma (13.1%), psychosocial disorders (7.9%), and visual
impairment (7.8%). Many diseases were, regardless of their prevalence, statistically associated with
AD. The strongest associations (odds ratio (OR) (95% confidence interval (CI))) were found in asthma
(2.10 (2.02–2.17)), allergic rhinitis (2.00 (1.91–2.10)), and irritable bowel syndrome (1.90 (1.56–2.31)).
A better understanding of the array of comorbidities associated with AD in children might help
improve their clinical management. Future longitudinal studies are encouraged to shed light on the
potential underlying pathophysiological mechanisms involved in the identified associations.
Keywords: atopic dermatitis; children; comorbidity; multimorbidity; prevalence; Spain
1. Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin disease of multifactorial etiology
characterized by age-specific skin lesions, xerosis, and highly pruritic outbreaks. Usually starting
in early childhood, AD significantly reduces patients’ quality of life [1,2] and increases healthcare
resource use [3]. According to the estimates of the International Study of Asthma and Allergies in
Childhood (ISAAC) [4], AD globally affects 15%–20% of children and 1%–3% of adults [5]. These
prevalence figures are growing worldwide and show clear geographical variances; AD is more frequent
in industrialized and high-income countries than in agriculture-based ones with low incomes [6,7].
Only one study to date exhaustively analyzed AD prevalence during childhood in Spain; it was
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conducted in 2008 using a population-based survey and concluded that AD affects around 30% of
6–7-year-olds [8].
Patients with AD are more susceptible to the development of allergic diseases and frequently suffer
from multimorbidity (i.e., coexistence of more than one chronic condition). Multiple studies link AD
during infancy to the future appearance of asthma and allergic rhinitis, with 80% of patients eventually
developing either of them or both [9]. Food allergies occur in 35% of children with AD [10], and cutaneous
infections and keratoconjunctivitis are more frequent than in the general population [11–13]. Psychiatric
and psychological disorders, especially attention deficit hyperactivity disorder (ADHD), depression,
or anxiety, are also more frequent in AD patients, possibly due to pruritus-induced lack of sleep,
psychological stress, and high levels of proinflammatory cytokines [9]. Other comorbidities of varying
nature such as cardiovascular diseases, type 2 diabetes, obesity, infections that go beyond cutaneous
over-infection, malignancies (e.g., lymphomas), or autoimmune disorders (e.g., alopecia areata, lupus
erythematosus, and inflammatory bowel disease) are also somehow linked to AD [12,14–16]. To the
best of our knowledge, there are no large-scale population-based publications specifically analyzing
the global comorbidity of AD during childhood.
Improving our knowledge on the comorbidity profile of children with AD is necessary for their
optimal clinical management, which should also consider the concurrence of different comorbidities,
and which could shed some light on the underlying pathophysiological mechanisms connecting AD to
other diseases. The characterization of the comorbidity profile of this population group should focus
not only on the identification of the most common diseases accompanying AD, but also on those that
are systematically associated to AD regardless of their prevalence. The results obtained in this regard
could help identify which comorbidities deserve special attention for the development of holistic,
person-centered clinical strategies for AD patients.
The objective of this large-scale, population-based study is to determine the prevalence of AD in
children under 18 years of age in a Mediterranean region of Spain, to exhaustively describe their most
prevalent comorbidities, and to analyze which diseases display an increased risk of appearance when
AD is present.
2. Experimental Section
2.1. Study Design and Population
We conducted a retrospective observational study in the EpiChron Cohort, which links
socio-demographic and clinical data from all the users of the public health system of the Spanish region
of Aragón [17]. This cohort is based on the information registered in the electronic health records
(EHRs) and clinical–administrative databases of approximately 98% of the inhabitants of Aragón
(reference population: 1.3 million people). Diagnoses are coded using the International Classification of
Primary Care, First Edition (ICPC–1) for primary care health records, or the International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD–9–CM) for hospital health records. Diagnoses
are subsequently grouped in expanded diagnostic clusters (EDCs) through the Johns Hopkins Adjusted
Clinical Groups (ACG®) System [18] (version 11.0, The Johns Hopkins University, Baltimore, MD, US).
A description of the cohort profile that served as the basis of more than 20 clinical–epidemiological
studies on chronic diseases, as well as of the information sources and data curation procedures used,
was published elsewhere [17].
For this study, we selected the individuals of the cohort aged 17 and under on 31 December 2015
(n = 216,291). Patients with AD were then identified through the appropriate diagnostic codes recorded
in their primary (i.e., ICPC–1 code “S87”) and/or hospital (i.e., ICD–9–CM code “691´, excepting
“691.0”) EHRs between 1 January 2015 and 31 December 2015. In Spain, AD is diagnosed clinically by
dermatologists or pediatricians based on medical history, the morphology and distribution of skin
lesions, and associated clinical signs [19]. Only patients living in Aragón and registered as users of the
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public health system during the year prior to the start of the study and during the complete one-year
follow-up period were included.
The Clinical Research Ethics Committee of Aragón (CEICA) approved this study (Research
protocol PI18/082) and waived the requirement to obtain the informed consent from patients given the
epidemiological nature of the project, which used anonymized data.
2.2. Study Variables
For each subject, we analyzed the following variables: sex, age as of 31 December 2015, nationality,
type of residence according to the type of administrative health area (urban, if 80% or more of the
population of the area is concentrated in one of the municipalities, or rural for the rest), deprivation index
of the area according to 26 socio-economic indicators ordered from least (Q1) to most (Q4) deprived
areas [20], and all chronic disease diagnoses, as well as those of specific, acute conditions considered
clinically relevant in AD (i.e., allergic rhinitis, conjunctivitis/keratitis, acne, otitis media/externa,
pharyngitis and tonsillitis, epistaxis, and acute respiratory tract infection) with at least five cases in the
population with AD. Medical conditions were considered chronic if included in the list of 114 EDCs
defined by Salisbury et al. as those conditions that normally last six months or more, including past
conditions that require ongoing disease or risk management, important conditions with a significant
risk of recurrence, or past conditions that have continuing implications for patient management [21].
Multimorbidity was defined as the co-occurrence of two or more conditions from said list.
2.3. Statistical Analysis
We performed a descriptive analysis of the frequency and prevalence (%) of AD in children based
on sex, age (i.e., 0–2-, 3–9-, 10–14-, and 15–17-year-olds), nationality, and residence area. We used logistic
regression models to calculate the likelihood of presenting AD according to each of the categories of the
aforementioned variables in the form of crude and age- and sex-adjusted odds ratios (ORs). Adjusted
ORs were compared setting statistical significance at p < 0.05. We then analyzed the socio-demographic
characteristics and comorbidity profile of children affected by AD. Results were calculated as means
and/or frequencies with their corresponding standard deviations and/or 95% confidence intervals (CI).
For the analysis of AD comorbidity, we described the frequency and prevalence of chronic diseases
and of the acute conditions of interest. For the identification of those comorbidities systematically
associated with AD, we used logistic regression models to calculate the occurrence risk of each
comorbidity (dependent variable) based on the presence or absence of AD (independent variable).
We obtained crude and adjusted ORs for sex, age, deprivation index, and rurality. We compared
adjusted ORs using the Bonferroni correction method for multiple comparisons to control familywise
error rates (for a total of 82 comparisons of diseases with at least five cases), setting statistical significance
at p < 0.00061. Statistical analyses were conducted using Stata software (Version 12.0, StataCorp LLC,
College Station, TX, US).
3. Results
3.1. Prevalence and Socio-Demographics of Atopic Dermatitis in Children
A total of 33,591 children under 18 years of age belonging to the cohort showed an AD diagnosis
during the study period, which resulted in an overall AD prevalence of 15.5% (Table 1). This prevalence
was slightly higher in girls compared to boys (15.8% vs. 15.3%; OR 1.04, 95% CI 1.01–1.06), and in
3–9- (20.8%; OR 1.98, 95% CI 1.91–2.06) and 10–14-year-old children (14.0%; OR 1.26, 95% CI 1.21–1.31)
compared to those aged 0–2 years (Table 2), although 15–17-year-old adolescents showed the lowest
prevalence rate (7.8%; OR 0.64, 95% CI 0.61–0.67). Spanish children were more frequently affected
by AD than those of different nationalities (ORs from 0.51 to 0.79). Regarding the area of residence,
AD prevalence was slightly lower in rural areas (OR 0.95, 95% CI 0.93–0.97) and in the most deprived
ones (OR 0.86, 95% CI 0.84–0.89). The mean age of children with AD was 7.72 years (SD 4.26), and the
proportion of boys and girls was similar (Table 3).
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Table 1. Frequency and prevalence (%) of atopic dermatitis (AD) in children of the EpiChron Cohort
aged 0–17 years in 2015 according to sex, age, nationality, area of residence and deprivation index.
EU—European Union.
Boys (n = 110,934) Girls (n = 105,357) Total (n = 216,291)
AD Prevalence n (%) n (%) n (%)
Sex 16,968 (15.3) 16,623 (15.8) 33,591 (15.5)
Age (years)
0–2 2110 (12.5) 1704 (10.7) 3814 (11.7)
3–9 9320 (20.5) 9230 (21.1) 18,550 (20.8)
10–14 4225 (13.7) 4358 (14.8) 8583 (14.2)
15–17 1313 (7.42) 1331 (8.19) 2644 (7.79)
Nationality
Spain 15,184 (16.1) 14,863 (16.6) 30,047 (16.3)
Eastern Europe 685 (10.0) 714 (10.8) 1399 (10.4)
Asia 150 (13.0) 145 (13.6) 295 (13.3)
North Africa 459 (11.6) 423 (11.4) 882 (11.5)
Sub-Saharan Africa 201 (13.3) 197 (14.9) 398 (14.1)
Latin America 232 (10.2) 223 (9.98) 455 (10.1)
EU and North America 52 (8.54) 54 (8.72) 106 (8.63)
Area of residence 1
Urban 10,297 (15.5) 10,321 (16.2) 20,496 (15.7)
Rural 6671 (15.0) 6302 (15.2) 13,095 (15.2)
Deprivation index 2
Q1 5259 (16.4) 5026 (16.4) 10,285 (16.4)
Q2 4085 (15.3) 4112 (16.0) 8197 (15.7)
Q3 3356 (15.4) 3316 (16.2) 6672 (15.8)
Q4 4268 (14.0) 4169 (14.6) 8437 (14.3)
1 Based on the type of administrative health area (urban, if 80% or more of the population of the area is concentrated
in one of the municipalities, or rural for the rest); 2 calculated at aggregated level per administrative health area
according to 26 socio-economic indicators and divided into quartiles from less (Q1) to more (Q4) deprived.
Table 2. Likelihood of presenting atopic dermatitis based on sex, age, nationality, area of residence
(urban/rural), and deprivation index of the area, calculated using logistic regression models.
Variable Crude OR 1 p-Value 2 Adjusted OR 3 p-Value
Sex
Boys Reference
Girls 1.04 (1.01–1.06) 0.002
Age (years)
0–2 Reference
3–9 1.98 (1.91–2.06) <0.001
10–14 1.26 (1.21–1.31) <0.001
15–17 0.64 (0.61–0.67) <0.001
Nationality
Spain Reference Reference
Sub-Saharan Africa 0.84 (0.76–0.94) 0.001 0.79 (0.71–0.88) <0.001
Asia 0.78 (0.69–0.89) <0.001 0.76 (0.67–0.86) <0.001
Eastern Europe 0.59 (0.56–0.63) <0.001 0.59 (0.56–0.62) <0.001
Latin America 0.57 (0.52–0.63) <0.001 0.61 (0.55–0.67) <0.001
North Africa 0.67 (0.62–0.72) <0.001 0.63 (0.58–0.67) <0.001
EU and North America 0.48 (0.40–0.59) <0.001 0.51 (0.41–0.62) <0.001
Area of residence
Urban Reference Reference
Rural 0.95 (0.93–0.97) <0.001 0.95 (0.93–0.97) <0.001
Deprivation index 4
Q1 Reference Reference
Q2 0.95 (0.92–0.98) 0.001 0.97 (0.94–1.00) 0.081
Q3 0.96 (0.92–0.99) 0.008 0.97 (0.94–1.00) 0.099
Q4 0.85 (0.82–0.88) <0.001 0.86 (0.84–0.89) <0.001
1 Odds ratio; 2 p-values less than 0.05 were considered significant and are highlighted in bold; 3 adjusted odds ratios
for age and sex; 4 calculated at aggregated level per administrative health area according to 26 socio-economic
indicators and divided into quartiles from less (Q1) to more (Q4) deprived.
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Table 3. Socio-demographic and clinical characteristics of children of the EpiChron Cohort aged
0–17 years with atopic dermatitis in 2015.
Characteristics Boys Girls Total
n (%) 16,968 (50.5) 16,623 (49.5) 33,591 (100)
Mean age, years (SD 1) 7.61 (4.29) 7.83 (4.24) 7.72 (4.26)
Age group, years (n, %)
0–2 2110 (12.4) 1704 (10.2) 3814 (11.3)
3–9 9320 (54.9) 9230 (55.5) 18,550 (55.2)
10–14 4225 (24.9) 4358 (26.2) 8583 (25.6)
15–17 1313 (7.74) 1331 (8.01) 2644 (7.87)
Nationality (n, %)
Spain 15,184 (89.5) 14,863 (89.4) 30,047 (89.5)
Eastern Europe 685 (4.04) 714 (4.30) 1399 (4.17)
Asia 150 (0.88) 145 (0.87) 295 (0.88)
North Africa 459 (2.71) 423 (2.55) 882 (2.63)
Sub-Saharan Africa 201 (1.18) 197 (1.19) 398 (1.19)
Latin America 232 (1.37) 223 (1.34) 455 (1.35)
EU and North America 52 (0.31) 54 (0.32) 106 (0.32)
Area of residence
Urban 2 (n, %) 10,297 (60.7) 10,321 (62.1) 20,618 (61.4)
Deprivation index 3 (n, %)
Q1 5259 (31.0) 5026 (30.2) 10,285 (30.6)
Q2 4085 (24.1) 4112 (24.7) 8197 (24.4)
Q3 3356 (19.8) 3316 (19.9) 6672 (19.9)
Q4 4268 (25.1) 4169 (25.1) 8437 (25.1)
Number of chronic diseases
(mean, SD) 1.67 (0.91) 1.58 (0.85) 1.62 (0.88)
Multimorbidity 4, yes (n, %) 7773 (45.8) 6794 (40.9) (43.4)
1 Standard deviation; 2 versus rural; 3 calculated at aggregated level per administrative health area according to 26
socio-economic indicators and divided into quartiles from less (Q1) to more (Q4) deprived; 4 defined as the presence
of two or more chronic diseases from a list of 114 conditions.
3.2. Comorbidity of Atopic Dermatitis in Children
Over 40% of children with AD showed multimorbidity, with a mean disease burden of 1.62 (SD
0.88) chronic diseases (Table 3). The most frequent chronic comorbidities in children with AD of
all ages and for both sexes were asthma (13.1%), psychosocial disorders (7.9%), visual impairment
(7.8%), congenital anomalies of limbs (5.8%), and developmental disorders (3.2%), among others. All
these comorbidities were more prevalent in the population with AD (Table 4). Upper respiratory tract
infections (54.4%), otitis media (12.8%), conjunctivitis (10.1%), and pharyngitis (7.9%) were amongst
the most prevalent acute conditions in this atopic cohort. The prevalence of both acute and chronic
comorbidities varied based on sex and age group (Table S1, Supplementary Materials), with notable
differences such as the earlier and more frequent occurrence of asthma, psycho-physiologic and
somatoform disorders in boys than girls.
Regardless of their prevalence and after adjusting by sex, age, rurality, and deprivation index,
the conditions that AD was significantly associated to the most were the following: (OR (95%
CI)) asthma (2.10 (2.02–2.17)), allergic rhinitis (2.00 (1.91–2.10)), and irritable bowel syndrome (1.90
(1.56–2.31)). A large and diverse number of comorbidities (i.e., cutaneous, neuropsychological,
musculoskeletal) were also significantly more prevalent in the atopic population (Table 4). Chronic
cutaneous disorders most associated to AD included psoriasis (1.62 (1.30–2.02)) and diseases of hair and
hair follicles, including alopecia and seborrheic dermatitis (1.51 (1.38–1.64)). Childhood psychosocial
disorders (1.53 (1.46–1.60)), developmental disorders (1.36 (1.27–1.45)), attention deficit disorder (1.37
(1.24–1.52)), and nonorganic sleep disorders (1.72 (1.55–1.90)) were the neuropsychological conditions
most associated with AD. Impulse control (1.56 (1.13–2.15)), psycho-physiologic and somatoform
disorders (1.47 (1.05–2.07)), and eating disorder (1.43 (1.12–1.83)) also presented high ORs, although not
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significant after applying the Bonferroni correction. Musculoskeletal comorbidities most frequent in
AD children included congenital anomalies of limbs, hands, and feet (1.53 (1.45–1.61)), kyphoscoliosis
(1.32 (1.22–1.42)), degenerative joint disease (1.42 (1.24–1.64)), and lower back pain (1.38 (1.15–1.65)).
Metabolic diseases such as obesity (1.18 (1.07–1.29)) and disorders of lipid metabolism (1.46 (1.32–1.63))
were also significantly more prevalent in the atopic population, whereas cardiac ones such as congenital
heart disease (1.25 (1.09–1.43)), cardiac valve disorders (1.57 (1.12–2.20)), and congestive heart failure
(1.56 (1.00–2.43)), as well as hematologic disorders like lymphoma and anemia (1.40 (1.14–1.71)),
presented high although not significant ORs.
Table 4. Prevalence of chronic comorbidities and of specific acute conditions (in italics) in children aged
0–17 years with atopic dermatitis (AD) in the EpiChron Cohort in 2015 (n = 33,591). Logistic regression
models were used to calculate odds ratios (OR) of prevalence for each comorbidity (dependent variable)
according to the presence or not of AD (independent variable). HIV—human immunodeficiency virus;
AIDS—acquired immune deficiency syndrome.
EDC 1 Comorbidity
Prevalence 2 Crude OR 3 Adjusted OR 5
p-Value 6
(n, %) (95% CI 4) (95% CI)
EAR11 Acute upper respiratory tract infection 18,256 (54.4) 1.52 (1.48–1.55) 1.42 (1.39–1.46) 0.0000
ALL04/05 Asthma 4384 (13.05) 1.94 (1.87–2.01) 2.10 (2.02–2.17) 0.0000
EAR01 Otitis media 4287 (12.8) 1.52 (1.47–1.58) 1.45 (1.40–1.51) 0.0000
EYE07 Conjunctivitis, keratitis 3388 (10.1) 1.45 (1.39–1.51) 1.39 (1.33–1.44) 0.0000
EAR09 Pharyngitis and tonsillitis 2662 (7.92) 1.67 (1.60–1.75) 1.74 (1.67–1.83) 0.0000
PSY14 Psychosocial disorders of childhood 2640 (7.86) 1.34 (1.28–1.40) 1.53 (1.46–1.60) 0.0000
EYE02 Visual impairment 2621 (7.80) 1.24 (1.19–1.30) 1.48 (1.42–1.55) 0.0000
ALL03 Allergic rhinitis 2386 (7.10) 1.50 (1.43–1.57) 2.00 (1.91–2.10) 0.0000
MUS11 Congenital anomalies of limbs 1952 (5.81) 1.53 (1.46–1.61) 1.53 (1.45–1.61) 0.0000
EAR06 Otitis externa 1197 (3.56) 1.49 (1.39–1.59) 1.47 (1.37–1.56) 0.0000
NUR19 Developmental disorder 1080 (3.22) 1.36 (1.27–1.45) 1.36 (1.27–1.45) 0.0000
SKN04 Acne 940 (2.80) 0.74 (0.70–0.80) 1.18 (1.10–1.27) 0.0000
MUS06 Kyphoscoliosis 816 (2.43) 0.88 (0.82–0.95) 1.32 (1.22–1.42) 0.0000
SKN13 Disease of hair and hair follicles 684 (2.04) 1.31 (1.21–1.43) 1.51 (1.38–1.64) 0.0000
END05 Other endocrine disorders 671 (2.00) 1.04 (0.96–1.13) 1.21 (1.12–1.32) 0.0000
EAR08 Deafness, hearing loss 652 (1.94) 1.41 (1.29–1.54) 1.52 (1.39–1.66) 0.0000
PSY19 Sleep disorders, nonorganic origin 519 (1.55) 1.76 (1.59–1.94) 1.72 (1.55–1.90) 0.0000
PSY05 Attention deficit disorder 484 (1.44) 1.03 (0.94–1.14) 1.37 (1.24–1.52) 0.0000
CAR11 Disorders of lipid metabolism 422 (1.26) 1.21 (1.09–1.34) 1.46 (1.32–1.63) 0.0000
EAR10 Epistaxis 331 (0.99) 1.56 (1.38–1.76) 1.57 (1.39–1.78) 0.0000
MUS03 Degenerative joint disease 238 (0.71) 1.02 (0.89–1.17) 1.42 (1.24–1.64) 0.0000
GAS09 Irritable bowel syndrome 132 (0.39) 1.83 (1.51–2.24) 1.90 (1.56–2.31) 0.0000
SKN12 Psoriasis 102 (0.30) 1.24 (1.00–1.54) 1.62 (1.30–2.02) 0.0000
RES04 COPD 7 66 (0.20) 1.72 (1.30–2.27) 1.76 (1.33–2.32) 0.0001
NUT03 Obesity 566 (1.68) 0.91 (0.84–1.00) 1.18 (1.07–1.29) 0.0005
MUS14 Lower back pain 141 (0.42) 0.91 (0.76–1.08) 1.38 (1.15–1.65) 0.0006
HEM08 Hematologic disorders, other 118 (0.35) 1.39 (1.14–1.71) 1.40 (1.14–1.71) 0.0012
CAR04 Congenital heart disease 250 (0.74) 1.31 (1.14–1.50) 1.25 (1.09–1.43) 0.0017
END04 Hypothyroidism 167 (0.50) 1.02 (0.86–1.20) 1.28 (1.08–1.52) 0.0036
PSY15 Eating disorder 79 (0.24) 1.13 (0.88–1.43) 1.43 (1.12–1.83) 0.0041
PSY16 Impulse control 47 (0.14) 1.22 (0.89–1.68) 1.56 (1.13–2.15) 0.0066
CAR06 Cardiac valve disorders 44 (0.13) 1.48 (1.06–2.06) 1.57 (1.12–2.20) 0.0083
RES11 Respiratory disorders, other 118 (0.35) 1.37 (1.12–1.68) 1.31 (1.07–1.61) 0.0087
GSU06 Chronic cystic disease of the breast 7 (0.02) 1.36 (0.59–3.11) 2.61 (1.13–6.06) 0.0253
PSY17 Psycho-physiological and somatoform disorders 42 (0.13) 1.28 (0.92–1.80) 1.47 (1.05–2.07) 0.0255
GAS02 Inflammatory bowel disease 13 (0.04) 1.31 (0.71–2.40) 1.86 (1.01–3.45) 0.0473
CAR05 Congestive heart failure 25 (0.07) 1.40 (0.90–2.18) 1.56 (1.00–2.43) 0.0496
CAR09 Cardiac arrhythmia 69 (0.21) 1.20 (0.92–1.55) 1.29 (0.99–1.67) 0.0599
GUR10 Prostatitis 14 (0.04) 1.77 (0.97–3.24) 1.77 (0.97–3.25) 0.0635
GTC01 Chromosomal anomalies 79 (0.24) 1.23 (0.96–1.57) 1.25 (0.98–1.60) 0.0729
MAL03 High impact malignant neoplasms 93 (0.28) 1.03 (0.82–1.28) 1.22 (0.98–1.53) 0.0805
EYE13 Diabetic retinopathy 16 (0.05) 1.67 (0.96–2.93) 1.64 (0.93–2.87) 0.0849
END06–09 Diabetes 81 (0.24) 1.09 (0.85–1.38) 1.23 (0.97–1.56) 0.0923
GSU08 Varicose veins of lower extremities 17 (0.05) 1.13 (0.67–1.90) 1.55 (0.91–2.63) 0.1053
NUR21 Neurologic disorders, other 200 (0.60) 1.12 (0.96–1.31) 1.13 (0.97–1.32) 0.1114
GUR03 Hypospadias, penile anomalies 106 (0.32) 1.23 (1.00–1.52) 1.19 (0.96–1.47) 0.1116
MAL12 Malignant neoplasms, colorectal 1 (0.00) 0.21 (0.03–1.54) 0.21 (0.03–1.55) 0.1258
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Table 4. Cont.
EDC 1 Comorbidity
Prevalence 2 Crude OR 3 Adjusted OR 5
p-Value 6
(n, %) (95% CI 4) (95% CI)
END02 Osteoporosis 5 (0.01) 1.60 (0.59–4.34) 2.15 (0.78–5.92) 0.1387
HEM01 Hemolytic anemia 86 (0.26) 1.09 (0.87–1.38) 1.19 (0.94–1.50) 0.1515
REN04 Nephritis, nephrosis 36 (0.11) 1.18 (0.82–1.69) 1.29 (0.90–1.85) 0.1698
CAR14/15 Hypertension 37 (0.11) 1.01 (0.71–1.43) 1.28 (0.90–1.82) 0.1770
MAL01 Malignant neoplasms of skin 8 (0.02) 1.40 (0.65–3.05) 1.69 (0.77–3.70) 0.1927
NUR08 Multiple sclerosis 5 (0.01) 1.81 (0.66–4.99) 1.95 (0.70–5.40) 0.1995
GAS08 Gastroesophageal reflux 7 (0.02) 0.62 (0.29–1.36) 0.60 (0.28–1.32) 0.2046
RHU03 Arthropathy 7 (0.02) 1.81 (0.77–4.27) 1.72 (0.73–4.04) 0.2157
INF04 HIV infection, AIDS 19 (0.06) 1.40 (0.84–2.31) 1.37 (0.83–2.27) 0.2190
HEM03 Thrombophlebitis 7 (0.02) 0.56 (0.26–1.22) 0.62 (0.28–1.36) 0.2332
RES06 Sleep apnea 12 (0.04) 1.48 (0.78–2.81) 1.43 (0.75–2.71) 0.2731
PSY08 Personality disorders 41 (0.12) 0.80 (0.58–1.12) 1.16 (0.84–1.62) 0.3687
GSU11 Peripheral vascular disease 7 (0.02) 1.12 (0.50–2.53) 1.44 (0.63–3.28) 0.3872
ALL06 Disorders of the immune system 34 (0.10) 1.12 (0.77–1.62) 1.15 (0.79–1.67) 0.4602
CAR03 Ischemic heart disease (excluding AMI 8) 17 (0.05) 0.86 (0.52–1.44) 0.83 (0.50–1.39) 0.4847
REC03 Chronic ulcer of the skin 10 (0.03) 0.73 (0.38–1.42) 0.79 (0.41–1.54) 0.4899
NUR07 Seizure disorder 222 (0.66) 1.01 (0.87–1.16) 1.05 (0.91–1.21) 0.5276
GTC02 Inherited metabolic disorders 5 (0.01) 0.80 (0.31–2.05) 0.76 (0.30–1.95) 0.5685
HEM02 Iron deficiency anemia 253 (0.75) 0.96 (0.84–1.10) 1.04 (0.91–1.19) 0.5794
REN05 Renal disorders, other 26 (0.08) 1.02 (0.67–1.56) 1.13 (0.74–1.72) 0.5819
PSY07 Schizophrenia, affective psychosis 51 (0.15) 0.99 (0.74–1.34) 1.09 (0.81–1.47) 0.5829
PSY02 Substance use 35 (0.10) 0.71 (0.50–1.01) 1.09 (0.76–1.56) 0.6293
HEM07 Hemophilia, coagulation disorder 6 (0.02) 1.21 (0.50–2.93) 1.20 (0.49–2.91) 0.6909
NUR03 Peripheral neuropathy, neuritis 43 (0.13) 0.90 (0.65–1.25) 0.94 (0.68–1.30) 0.7011
EYE06 Cataract, aphakia 9 (0.03) 0.83 (0.41–1.67) 0.87 (0.43–1.77) 0.7051
NUR16 Spinal cord injury/disorders 11 (0.03) 0.92 (0.49–1.74) 0.89 (0.47–1.68) 0.7091
MAL16 Acute leukemia 8 (0.02) 0.78 (0.37–1.63) 0.88 (0.42–1.86) 0.7403
PSY09 Depression 44 (0.13) 0.67 (0.49–0.92) 1.05 (0.76–1.44) 0.7751
CAR16 Cardiovascular disorders, other 79 (0.24) 0.96 (0.76–1.22) 1.04 (0.81–1.32) 0.7795
GUR09 Renal calculi 14 (0.04) 1.02 (0.57–1.80) 1.08 (0.61–1.93) 0.7817
ADM02 Surgical aftercare 25 (0.07) 0.99 (0.64–1.51) 1.06 (0.69–1.63) 0.7922
NUR05 Cerebrovascular disease 22 (0.07) 1.04 (0.66–1.64) 1.04 (0.66–1.64) 0.8678
GUR01 Vesicoureteral reflux 6 (0.02) 0.99 (0.41–2.36) 1.07 (0.45–2.58) 0.8768
INF01 Tuberculosis infection 79 (0.24) 0.88 (0.69–1.11) 1.01 (0.80–1.29) 0.9155
PSY01 Anxiety, neuroses 72 (0.21) 0.69 (0.54–0.89) 1.00 (0.78–1.28) 0.9718
1 Expanded diagnostic clusters; 2 comorbidities appear in descending order of the p-value of the comparison;
only diseases with a frequency of five or more cases are represented; 3 confidence interval; 4 unadjusted odds
ratios; 5 odds ratios adjusted by sex, age, deprivation index and area (rural/urban); 6 p-values for the adjusted OR;
p-values < 0.00061 are highlighted in bold as significant according to Bonferroni correction for multiple comparisons;
7 chronic obstructive pulmonary disease; 8 acute myocardial infarction.
4. Discussion
In this large-scale population-based study, we used real-world data to analyze AD prevalence
in 216,291 pediatric users of the Spanish public health system. We exhaustively characterized the
comorbidities of all 33,591 boys and girls with AD in the EpiChron Cohort, with a focus on the
most prevalent chronic diseases and on those that were associated the most to AD regardless of
their prevalence.
The prevalence of AD obtained in our population (15.5%) was similar to that found in other
industrialized countries such as Sweden and Japan (16%) [7]. The soundest study to date in Spain on
AD prevalence in children reported slightly higher rates in 6–7-year-olds (28%) than the ones shown by
3–9-year-olds in our population (22%) [8]. However, while the former study used surveys completed by
children’s parents, we analyzed patients’ clinical histories to extract professionally diagnosed cases of
AD, which could explain the variations in prevalence. Concurring with previous studies, and although
prevalence differences between boys and girls were minimal in our population, girls were more affected
by AD than boys [22,23].
Surprisingly, AD prevalence was similar in native (Spanish) and Asian or sub-Saharan African
children, who come from areas of traditionally low prevalence [7]. Our results seem to support the
theory that environmental factors related to industrialization could increase the risk of AD in people
who migrate to industrialized countries [24]. However, we had no data on the immigration status of
children or the age at which they migrated to Spain. This hypothesis also concurs with the well-known
“hygiene theory” and with the slightly higher AD prevalence rates found in children from urban areas
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compared to rural environments [23,25]. Similarly, our findings, which reflected higher AD prevalence
rates in children belonging to higher socio-economic levels, were consistent with the results reported
in seven-year-old children in Great Britain, who also showed differences in this regard [26]. One might
expect that more readily available access to healthcare could account for the observed increase in the
prevalence of AD in children from urban and/or less deprived settings. However, the public health
system in Spain provides equal conditions of access to care regardless of the area and, therefore, we
believe that said increase in prevalence would be due to other factors.
In order to offer a global characterization of the comorbidity profile present in these children, we
followed a two-pronged approach; we described both the most common comorbidities irrespective
of their association to AD, as well as those with an increased risk of occurrence in children with a
diagnosis of AD. The co-occurrence of these comorbidities could be a cause or a consequence of AD
or share with it a common etiological mechanism. In line with previous studies, our investigation
evidenced that children and adolescents with AD frequently suffer from multimorbidity (43%) and
show an increased risk of developing a great number of diseases and symptoms of varying natures.
Prevalence rates of asthma, the most frequent AD comorbidity in our population, were lower
(13%) than those reported in 3–5-year-olds in two Italian studies (24%) [27], and in 17-year-olds and
under in the USA (25%) [28]. Furthermore, we found that atopy-related comorbidity prevalence rates
increased with age; asthma and allergic reactions debuted at ages 3–9, followed by allergic rhinitis in
the group of 10–14-year-olds in a sequence of increasing prevalence rates for different atopic conditions
known as the “atopic march” [29].
In consonance with several studies highlighting the importance of mental health disorders [30–33]
and suicidal ideation [34] in children with AD, psychosocial disorders were the second most prevalent
chronic condition (7.9%) in our study population. Although the determining factors of this association
are diverse, previous studies suggest that sleep disturbances play a key role in mental health disorder
development in children with AD [31,35–37], particularly in conditions such as ADHD [38]. ADHD,
in fact, was also more frequent in our study in children with AD compared to those without. These and
other psychiatric disorders can be present even in preschool children with atopic eczema, although in
our sample they become a relevant comorbidity in 10-year-olds and above [39].
Regarding visual impairment, the third most frequent comorbidity in our study (7.8%), Pols et
al. [40] found an association between AD (OR (95% CI)) and blepharitis/styes/chalazion (1.53 (1.29–1.81)),
infectious conjunctivitis (1.53 (1.20–1.81)), and allergic conjunctivitis (1.99 (1.59–2.49)) after analyzing a
nationwide primary care database of children in the Netherlands. However, since the exact prevalence
of each of the diagnoses included in the visual impairment EDC was unavailable, we were unable to
contrast their results with our own. Our results for irritable bowel syndrome (1.90 (1.56–2.31)) were
consistent with other recently published studies on children and adults with AD [41,42].
Musculoskeletal comorbidities, such as congenital anomalies of limbs, hands, and feet,
kyphoscoliosis, degenerative joint disease, and lower back pain were more frequent in AD pediatric
patients, who were shown to share common risk factors for injuries, including the aforementioned
sleep disturbances, distractions due to chronic itch, the sedative effects of antihistamine drugs, and
psychological comorbidities [43]. Additionally, low vitamin D blood levels in AD patients might also
contribute to the skeletal burden [44]. Pols et al. found a higher prevalence of foot/toe-related symptoms
(1.39 (1.20–1.60)) and acquired deformities of the limbs (1.39 (1.20–1.60)) in their study [40]; however,
the association between AD and congenital limb anomalies or kyphoscoliosis was not established.
Otological conditions, both acute and chronic, were also more prevalent in patients with AD. Otitis
media was present in 13% of patients in our sample and was especially significant in 0–9-year-olds,
showing higher rates than those found by Silverberg et al. in the United States of America (USA)
(5%) [45]. A recent systematic review also found a higher risk of infectious otitis in patients with
AD [45], whereas deafness and hearing loss, which had an adjusted OR of 1.52 (1.39–1.66) in our
sample, had not been previously associated with AD.
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The prevalence of autoimmune diseases is reportedly higher in children with AD [46]. Alopecia
areata frequently shows the strongest association [46,47], which would be consistent with the higher
prevalence of hair and hair follicles diseases found in our sample. Psoriasis was also more prevalent in
our population with AD, as previously described by Pols et al. [40]. The association of central obesity
with AD was already reported, especially in women [16]. A recent study published by our group on
14-year-olds and below concluded that the prevalence of overweight, obesity, and dyslipidemia was
greater in those with AD [48], which concurs with our present findings.
We have to highlight the existence of some comorbidities of varying nature that, although not
significant after applying the Bonferroni correction for multiple comparisons, deserve special attention
since they could be potentially associated with AD, as they presented some of the highest ORs of
our study. This is the case of chronic cystic disease of the breast (2.61 (1.13–6.06)) that, despite its
very low prevalence (0.02%), was the condition AD was associated to the most, and which had not
been previously reported in other studies that we know of. Congenital heart diseases and cardiac
valve disorders also presented high ORs and had not been described in the existing literature either.
As certain authors already suggested, AD could potentially constitute a risk factor for the development
of cardiovascular diseases during adulthood [15,49]. Inflammatory bowel disease, although infrequent,
also showed one of the highest adjusted ORs (1.86 (1.01–3.45)). Previous studies support the association
of both diseases in children [46,50] and, in fact, inflammatory bowel disease shares 39 genetic risk loci
with AD, also suggesting a genetic cause [51].
Our results could help better understand the comorbidity of AD and improve its overall
management and treatment, providing patients with holistic and person-centered care. Nonetheless,
statistical associations do not necessarily translate into the existence of causal relationships, and these
findings should be interpreted with caution. Although many common underlying factors are well
documented in the existing literature, some of the associations found in our study were not previously
considered and could set the basis for future studies aimed at identifying common pathophysiological
pathways connecting AD to other conditions of varying nature.
The main strength of our work lies in its large-scale, population-based characteristics, as it
included almost every child with an AD diagnosis belonging to the reference population area. Moreover,
AD comorbidity was exhaustively analyzed through the study of every chronic disease diagnosis
in both primary and hospital care, not only the most prevalent or relevant ones. The use of EHRs
guaranteed the reliability of data, which underwent continuous quality control revisions to ensure its
accuracy. The main limitation of our study was its cross-sectional nature, which made determining
the chronological order of appearance of diseases impossible, thus hindering the identification of
cause–effect relationships between AD and its comorbidities. Furthermore, EHRs were not specifically
designed for the purposes of this research, thus leading to potential over- or under-reporting of certain
diseases. Moreover, some variables of interest for the study, such as lifestyle habits (e.g., lack of exercise,
unhealthy eating), environmental information (e.g., air pollution, weather conditions), or specific data
on immigration status of children were not available in the cohort.
5. Conclusions
The present study evidences that AD is prevalent in children and that it is systematically associated
with some relevant non-dermatological conditions of neuropsychiatric, visual, cardio-metabolic,
and autoimmune nature, among others. Our results highlight the importance of monitoring the
array of comorbidities surrounding AD during childhood, which could help improve their clinical
management and plan interventions aimed at preventing their development. Future longitudinal
studies are encouraged to shed light on the underlying pathophysiological mechanisms involved in
these associations.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/6/1632/s1:
Table S1. Prevalence of the 10 most frequent diseases (both acute or chronic) in children with atopic dermatitis,
according to age and sex.
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